Genenta Science (NASDAQ:GNTA) Shares Down 10.7% – Here’s What Happened

Posted by Francis Steltz on Sep 18th, 2026

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report)’s share price traded down 10.7% during mid-day trading on Wednesday . The stock traded as low as $0.7130 and last traded at $0.7413. Approximately 72,950 shares changed hands during mid-day trading, an increase of 53% from the average daily volume of 47,689 shares. The stock had previously closed at $0.8301.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Get Our Latest Research Report on GNTA

Genenta Science Stock Down 8.7%

The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35. The firm’s fifty day simple moving average is $1.23 and its 200 day simple moving average is $1.12.

Institutional Investors Weigh In On Genenta Science

An institutional investor recently bought a new stake in Genenta Science stock. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 360,000 shares of the company’s stock, valued at approximately $536,000. Eurizon Capital SGR S.p.A. owned 1.88% of Genenta Science as of its most recent filing with the SEC. Institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

(Get Free Report)

Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on developing cell and gene therapies for cancer. The company’s approach is designed to use genetically modified hematopoietic stem cells to deliver therapeutic proteins directly within the tumor microenvironment, with the goal of improving the effectiveness and tolerability of cancer treatment.

Genenta’s lead investigational program, Temferon, is an autologous stem-cell-based gene therapy intended to generate immune cells capable of producing interferon-alpha at tumor sites.